Abingdon Health Plc (ABDXF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abingdon Health Plc (ABDXF), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 54/100 puan alıyor.
Son analiz: 16 Mar 2026Abingdon Health Plc (ABDXF) Sağlık ve Boru Hattı Genel Bakışı
Abingdon Health Plc specializes in diagnostic device development, manufacturing, and distribution, focusing on rapid testing solutions like COVID-19 tests and nucleic acid lateral flow immunoassays. The company serves a global market, offering both product sales and contract services within the medical diagnostics industry.
Yatırım Tezi
Abingdon Health Plc presents a focused play on the diagnostics market, particularly in rapid testing solutions. With a market capitalization of $0.01 billion, the company's negative P/E ratio of -9.12 reflects current challenges in achieving profitability, despite a gross margin of 37.1%. Key value drivers include expansion of its contract manufacturing services and successful commercialization of its AppDx technology. Growth catalysts include potential partnerships and increased demand for rapid diagnostic solutions. Potential risks include competition from established players and the need to achieve sustainable profitability. Investors should monitor the company's ability to leverage its existing product portfolio and strategic collaborations to drive revenue growth and improve financial performance.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.01 billion indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -9.12 reflects current unprofitability, requiring careful monitoring of future earnings.
- Gross margin of 37.1% demonstrates the potential for profitability if operational efficiencies are improved.
- Beta of 0.18 suggests low volatility compared to the overall market, indicating a relatively stable stock.
- Collaboration with Abcam plc provides access to a broader market and enhances product development capabilities.
Rakipler & Benzerleri
Güçlü Yönler
- Established expertise in lateral flow technology.
- Manufacturing capabilities for diagnostic devices.
- Collaboration with Abcam plc.
- Diverse product portfolio including COVID-19 tests.
Zayıflıklar
- Negative P/E ratio indicating current unprofitability.
- Small market capitalization.
- Dependence on COVID-19 testing market.
- Limited brand recognition compared to larger competitors.
Katalizörler
- Upcoming: Potential new contract manufacturing agreements.
- Ongoing: Commercialization of AppDx technology.
- Ongoing: Expansion of diagnostic test portfolio.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Geographic expansion into new markets.
Riskler
- Potential: Intense competition from established diagnostic companies.
- Potential: Decline in demand for COVID-19 testing.
- Potential: Regulatory changes in the healthcare industry.
- Potential: Economic downturn affecting healthcare spending.
- Ongoing: Negative P/E ratio indicating current unprofitability.
Büyüme Fırsatları
- Expansion of Contract Manufacturing Services: Abingdon Health can leverage its manufacturing capabilities to secure more contract manufacturing agreements with other healthcare companies. The global contract manufacturing market for medical devices is projected to reach $108.1 billion by 2027, presenting a significant opportunity for Abingdon Health to increase its revenue and profitability. Timeline: Ongoing.
- Commercialization of AppDx Technology: The AppDx technology, which transforms smartphones into lateral-flow readers, has the potential to disrupt the point-of-care diagnostics market. By partnering with healthcare providers and diagnostic test developers, Abingdon Health can drive adoption of AppDx and generate recurring revenue through software licenses and data analytics services. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Abingdon Health can pursue strategic partnerships and collaborations with other companies in the healthcare industry to expand its product portfolio and market reach. The collaboration with Abcam plc is a positive example, and further partnerships could accelerate growth. Timeline: Ongoing.
- Development of New Diagnostic Tests: Abingdon Health can invest in the development of new diagnostic tests for various diseases and conditions. The global diagnostics market is expected to reach $137.7 billion by 2028, driven by advancements in technology and increasing demand for personalized medicine. Timeline: Ongoing.
- Geographic Expansion: Abingdon Health can expand its operations into new geographic markets, particularly in developing countries where there is a growing need for affordable and accessible diagnostic tests. The company can leverage its existing product portfolio and manufacturing capabilities to establish a presence in these markets. Timeline: Ongoing.
Fırsatlar
- Expansion of contract manufacturing services.
- Commercialization of AppDx technology.
- Development of new diagnostic tests.
- Geographic expansion into developing markets.
Tehditler
- Intense competition from established diagnostic companies.
- Decline in demand for COVID-19 testing.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting healthcare spending.
Rekabet Avantajları
- Proprietary lateral flow technology.
- Established manufacturing capabilities.
- Strategic collaboration with Abcam plc.
- Expertise in diagnostic test development.
ABDXF Hakkında
Abingdon Health Plc, incorporated in 2008 and headquartered in York, United Kingdom, operates within the medical diagnostics industry, focusing on the development, manufacture, and distribution of a range of diagnostic devices. The company's product portfolio includes the AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test, as well as nucleic acid lateral flow immunoassays, PCRD and PCRD FLEX for rapid readouts post isothermal amplification, the Abingdon Simply Test range of self-tests, and the 2019-nCoV Antigen Test for qualitative detection of antigens to SARS-CoV-2. Abingdon Health also offers AppDx, a customizable image capturing technology that transforms smartphones into lateral-flow readers. Beyond its proprietary products, Abingdon Health provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. The company extends its expertise through consultancy services to businesses operating in the healthcare technology sector. Abingdon Health has a collaboration and co-marketing agreement with Abcam plc, enhancing its market reach and product development capabilities.
Ne Yaparlar
- Develops rapid diagnostic tests for infectious diseases.
- Manufactures lateral flow immunoassays.
- Offers COVID-19 antibody and antigen tests.
- Provides contract manufacturing services for diagnostic devices.
- Offers a smartphone-based lateral flow reader technology (AppDx).
- Provides consultancy services to healthcare technology businesses.
İş Modeli
- Sales of rapid diagnostic tests (e.g., COVID-19 tests).
- Contract manufacturing for other diagnostic companies.
- Licensing and sales of AppDx technology.
- Consultancy services for healthcare businesses.
Sektör Bağlamı
Abingdon Health Plc operates in the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for rapid and accurate testing solutions. The market is driven by factors such as the growing prevalence of infectious diseases, the increasing adoption of point-of-care diagnostics, and advancements in biotechnology. Competitors include companies like CRPOF (CareRx Corporation), EIGRQ (Eurofins Scientific SE), MNNDF (MIND Technology, Inc.), NOXOF (Noxopharm Ltd), and PXXLF (Pro-Dex, Inc.). Abingdon Health's focus on lateral flow technology positions it to capitalize on the demand for rapid and cost-effective diagnostic tests.
Kilit Müşteriler
- Healthcare providers (hospitals, clinics).
- Diagnostic test developers.
- Pharmaceutical companies.
- Research institutions.
Finansallar
Grafik & Bilgi
Abingdon Health Plc (ABDXF) hisse senedi fiyatı: Price data unavailable
Son Haberler
ABDXF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
ABDXF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
ABDXF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, ABDXF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Christopher William Hand
CEO
Christopher William Hand serves as the CEO of Abingdon Health Plc, managing a team of 113 employees. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Abingdon Health, he held leadership positions at various companies, focusing on commercial strategy, product development, and market expansion. He brings a wealth of knowledge in driving growth and innovation within the healthcare sector.
Sicil: Under Christopher William Hand's leadership, Abingdon Health has focused on expanding its product portfolio and strengthening its manufacturing capabilities. Key achievements include securing strategic collaborations and launching new diagnostic tests. He has overseen the development and commercialization of the AppDx technology, as well as navigated the company through the challenges and opportunities presented by the COVID-19 pandemic.
ABDXF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Abingdon Health Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price volatility.
- Lack of regulatory oversight.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile and disclosure status.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established manufacturing capabilities.
- Collaboration with Abcam plc.
- Development of proprietary technology (AppDx).
- Operating history since 2008.
- CEO with experience in the healthcare industry.
Abingdon Health Plc Hissesi: Cevaplanan Temel Sorular
ABDXF için değerlendirilmesi gereken temel faktörler nelerdir?
Abingdon Health Plc (ABDXF) şu anda yapay zeka skoru 54/100, orta puanı gösteriyor. Temel güçlü yan: Established expertise in lateral flow technology.. İzlenmesi gereken birincil risk: Potential: Intense competition from established diagnostic companies.. Bu bir finansal tavsiye değildir.
ABDXF MoonshotScore'u nedir?
ABDXF şu anda MoonshotScore'da 54/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
ABDXF verileri ne sıklıkla güncellenir?
ABDXF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler ABDXF hakkında ne diyor?
ABDXF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
ABDXF'a yatırım yapmanın riskleri nelerdir?
ABDXF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from established diagnostic companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
ABDXF'ın P/E oranı nedir?
ABDXF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ABDXF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
ABDXF aşırı değerli mi, yoksa düşük değerli mi?
Abingdon Health Plc (ABDXF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
ABDXF'ın temettü verimi nedir?
Abingdon Health Plc (ABDXF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- OTC market data may be limited or delayed.
- AI analysis pending for ABDXF.